Keywords
Biphosphonates
Adverse effects
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To describe a clinical case of bilateral osteonecrosis of the jaw (Stage 3) related to the use of pamidronate disodium (Aredia®) in an oncology patient and to establish a brief review of the literature. Case details: This is a 78-year-old patient undergoing palliative treatment for prostate cancer (adenocarcinoma Gleason 7) and diagnosed with drug-related osteonecrosis of the jaw (ONJ) in the midface. Aggressive surgical treatment combined with adjuvant drug therapy was performed. The patient evolved well with complete resolution of symptoms, absence of recurrence and improvement in quality of life. Final considerations: The pathophysiology of ONJ is not fully understood and contains many risk factors, therefore, definitive treatment protocols have not yet been established. It is important to note that the removal of necrotic bone is important in the treatment of ONJ, with surgical resections being invasive and necessary procedures in advanced-stage patients, especially in stage 3 patients. The surgical protocol presented in this study shows promising results for the surgical management of advanced stages in high-risk ONJ patients, however, further studies are needed for definitive and effective treatment.
References
AHDI HS, et al. Medication-induced osteonecrosis of the jaw: a review of cases from the food and drug administration adverse event reporting system (FAERS). BMC Pharmacol Toxicol, 2023; 24(1): 15.
ANASTASILAKIS AD, et al. Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS. J Clin Endocrinol Metab, 2022; 107: 1441–1460.
ARQUEROS-LEMUS M, et al. Pentoxifylline and tocopherol for the treatment of osteoradionecrosis of the jaws. a systematic review. Med Oral Patol Oral Cir Bucal, 2023; 28(3): 293-300.
BETH-TASDOGAN NH, et al. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev, 2022; 7(7): 12432.
BOSTON B, et al. Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients. J Am Geriatr Soc, 2023; 71(8): 2640-2652.
BRANDÃO TB e MIGLIORATI CA, et al. Diagnóstico e tratamento odontológico para pacientes com câncer. Rio de Janeiro: GEN, 2021; 1: 173.
CHOI NR, et al. Surgical treatment of medication-related osteonecrosis of the jaw: a retrospective study. Int J Environ Res Public Health, 2020; 17: 1–9.
EGUCHI T, et al. The assessment of surgical and non-surgical treatment of stage II medication-related osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal, 2017; 22(6): 788-795.
FUSCO V, et al. Comment on medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline summary. J Oncol Pract, 2020; 16: 142–145.
GOKER F, et al. Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review. Eur Rev Med Pharmacol Sci, 2021; 25(6): 2662-2673.
HE L, et al. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci, 2020; 12(1): 30.
HUBER FA, et al. Medication-related osteonecrosis of the jaw-comparison of bone imaging using ultrashort echo-time magnetic resonance imaging and cone-beam computed tomography. Invest Radiol, 2020; 55: 160–167.
KIM JW, et al. Medication related osteonecrosis of the jaw: 2021 position statement of the korean society for bone and mineral research and the korean association of oral and maxillofacial surgeons. J Bone Metab, 2021; 28: 279–296.
KUEHN S, et al. Medication-related osteonecrosis: why the jawbone? Dent J (Basel), 2023; 11(5): 109.
LORENZO-POUSO AI, et al. Medication-related osteonecrosis of the jaw: a critical narrative review. J Clin Med. 2021; 10(19): 4367.
MOLL S, et al. Patients' quality of life improves after surgical intervention of stage III medication-related osteonecrosis of the jaw. Oral Maxillofac Surg, 2021; 25(3): 359-366.
OTTO S, et al. Infection as an important factor in medication-related osteonecrosis of the Jaw (MRONJ). Medicina (Kaunas). 2021; 57(5): 463.
RUGGIERO SL, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg, 2014; 72: 1938–1956.
RUGGIERO SL, et al. American association of oral and maxillofacial surgeons’ position paper on medication-related osteonecrosis of the jaws. J Oral Maxillofac Surg, 2022; 80: 920–943.
SAHIN O, et al. Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Braz J Otorhinolaryngol, 2022; 88: 613–620.
SLOWIK L, et al. Pharmacological treatment of medication-related osteonecrosis of the jaw (mronj) with pentoxifylline and tocopherol. J Clin Med, 2025; 14(3): 974.
TADOKORO Y, et al. Risk factors associated with prognosis of patients with medication-related osteonecrosis of the jaw. Head Neck, 2024; 46(2): 282-290.
TOMO S, et al. Fluorescence-guided surgical management of medication-related osteonecrosis of the jaws. Photodiagnosis Photodyn Ther, 2020; 32: 102003.
VILELA-CARVALHO LN, et al. Osteonecrosis de los maxilares relacionados con el uso de medicamentos: Diagnóstico, tratamiento y prevención. CES Odontología, 2019; 31(2): 48–63.